

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

<https://doi.org/10.1038/s41586-022-04594-4>

Received: 6 February 2022

Accepted: 28 February 2022

Published online: 3 March 2022

Open access

 Check for updates

Sho Iketani^{1,2,8}, Lihong Liu^{1,8}, Yicheng Guo^{1,8}, Liyuan Liu^{3,8}, Jasper F.-W. Chan^{4,5,8}, Yiming Huang³, Maple Wang¹, Yang Luo¹, Jian Yu¹, Hin Chu^{4,5}, Kenn K.-H. Chik^{4,5}, Terrence T.-T. Yuen⁴, Michael T. Yin^{1,6}, Magdalena E. Sobieszczyk^{1,6}, Yaoxing Huang¹, Kwok-Yung Yuen^{4,5}, Harris H. Wang^{3,7}, Zizhang Sheng¹ & David D. Ho^{1,2,6}✉

The identification of the Omicron (B.1.1.529.1 or BA.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021¹ immediately caused concern owing to the number of alterations in the spike glycoprotein that could lead to antibody evasion. We² and others^{3–6} recently reported results confirming such a concern. Continuing surveillance of the evolution of Omicron has since revealed the rise in prevalence of two sublineages, BA.1 with an R346K alteration (BA.1+R346K, also known as BA.1.1) and B.1.1.529.2 (BA.2), with the latter containing 8 unique spike alterations and lacking 13 spike alterations found in BA.1. Here we extended our studies to include antigenic characterization of these new sublineages. Polyclonal sera from patients infected by wild-type SARS-CoV-2 or recipients of current mRNA vaccines showed a substantial loss in neutralizing activity against both BA.1+R346K and BA.2, with drops comparable to that already reported for BA.1 (refs. ^{2,3,5,6}). These findings indicate that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus similarly threaten the efficacies of current vaccines. BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab)⁷, which had retained appreciable activity against BA.1 and BA.1+R346K (refs. ^{2–4,6}). This finding shows that no authorized monoclonal antibody therapy could adequately cover all sublineages of the Omicron variant, except for the recently authorized LY-CoV1404 (bebtelovimab).

The rise of the Omicron (B.1.1.529) variant to become the dominant variant of SARS-CoV-2 globally has been remarkable⁸. Continuing surveillance of its evolution in the population in December 2021 and January 2022 has revealed that the proportion of the original form, BA.1, has been decreasing steadily whereas the proportions of two other sublineages have increased noticeably (Fig. 1a). In fact, the BA.1+R346K sublineage now accounts for about 40% of Omicron sequences globally, and about 35–60% in New Zealand, the UK and the USA. On the other hand, the BA.2 sublineage accounts for only about 10% of Omicron sequences globally, but it is not only on the rise but also the dominant form in countries such as Denmark, India and South Africa. These three sublineages of Omicron share 21 alterations in the spike protein, wherein BA.2 contains 8 unique alterations and BA.1 contains 13 unique alterations (Fig. 1b). Of course, BA.1+R346K has one alteration more than BA.1. Given these differences, their antigenic properties cannot be assumed to be the same or similar.

Serum neutralization of sublineages

Therefore, we first investigated the sensitivity of the Omicron sublineages to neutralization by polyclonal sera from convalescent individuals or individuals given mRNA vaccines, with or without a booster shot. These serum samples, as well as the pseudovirus neutralization assay used, were identical to ones previously reported². The wild-type D614G pseudovirus was included as a comparator. As was observed and reported for BA.1 (refs. ^{2,3,5,6}), a marked and significant loss of neutralizing activity of the serum against BA.1+R346K and BA.2 relative to D614G was noted, with neutralizing titres for numerous samples dropping below the limit of detection (Fig. 1c). The loss of neutralizing activity against BA.1+R346K or BA.2 sublineages was less prominent for sera obtained from individuals who received a booster vaccination (Fig. 1c, right panel), consistent with reported findings for BA.1 (refs. ^{2,3,6}). Among these samples, the mean serum neutralizing titres against Omicron sublineages were significantly lower than the mean

¹Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ²Department of Microbiology and Immunology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ³Department of Systems Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ⁴State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China. ⁵Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong Special Administrative Region, China. ⁶Division of Infectious Diseases, Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ⁷Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA. ⁸These authors contributed equally: Sho Iketani, Lihong Liu, Yicheng Guo, Liyuan Liu, Jasper F.-W. Chan. ✉e-mail: dh2994@cumc.columbia.edu




Fig. 1 | BA.2 exhibits a similar serum neutralization profile to those of BA.1 sublineages. **a**, Proportions of BA.1, BA.1+R346K and BA.2 in B.1.1.529 sequences on GISAID over the latter half of December 2021 and January 2022. The value in the upper right corner of each box denotes the cumulative number of Omicron sequences. **b**, Alterations in the B.1.1.529 lineage. NTD, N-terminal domain; RBD, receptor-binding domain; SD1, subdomain 1; SD2, subdomain 2; FP, fusion peptide; HR1, heptad repeat 1; CH, central helix; CD, connector domain; HR2, heptad repeat 2; CT, cytoplasmic tail. **c**, Pseudovirus


neutralization by convalescent and vaccinee sera. $n = 10, 12, 13$ and 15 biologically independent serum samples, respectively, for convalescent, mRNA-1273, BNT162b2 and boosted groups. The values above the points indicate geometric means. The numbers in parentheses denote the numbers of samples above the limit of detection (LOD) of 100. Values below the LOD are arbitrarily plotted to allow for visualization of each sample. P values were determined by a two-sided Friedman test followed by Dunn's multiple comparisons test.

titre for D614G; although the mean titre was slightly lower for BA.2, the difference from that of the BA.1 sublineages did not reach statistical significance ($P = 0.242$). Finally, we confirmed the pseudovirus neutralization data by testing a separate set of sera from individuals given mRNA vaccines for neutralization of authentic viruses (Extended Data Fig. 1 and Extended Data Table 1). As above, neutralizing titres dropped significantly against authentic BA.2 virus relative to D614G.

Antibody neutralization of sublineages

To further examine antigenic differences in the spike protein of these Omicron sublineages, a panel of 19 neutralizing monoclonal antibodies was used as probes. Seventeen were directed to different epitope

clusters (classes 1–4) in the receptor-binding domain (RBD), whereas two were directed to the N-terminal domain (NTD). These antibodies included REGN10987 (imdevimab)⁹, REGN10933 (casirivimab)⁹, COV2-2196 (tixagevimab)¹⁰, COV2-2130 (cilgavimab)¹⁰, LY-CoV555 (bamlanivimab)¹¹, CB6 (etesevimab)¹², Brie-196 (amubarvimab)¹³, Brie-198 (romlusevimab)¹³, S309 (sotrovimab)⁷, LY-CoV1404 (bebtelovimab)¹⁴, ADG-2 (ref. 15), DH1047 (ref. 16) and S2X259 (ref. 17), as well as 1-20, 2-15, 2-7, 4-18, 5-7 (ref. 18) and 10-40 (ref. 19) from our group. Overall, 17 of the 19 monoclonal antibodies were either totally inactive or severely impaired in neutralizing BA.2 (Fig. 2a), similar to previous findings for BA.1 and BA.1+R346K (ref. 2) but with important differences (Fig. 2b). All class 4 antibodies tested lost greater neutralizing potency against BA.2 versus BA.1 sublineages. Two class 3 antibodies, COV2-2130 and 2-7,



b

Fold change in IC ₅₀ relative to D614G	RBD mAbs														NTD mAbs				
	Class 1			Class 2				Class 3				Class 4			4-18	5-7			
	CB6	Brii-196	1-20	REGN 10933	COV2-2196	LY-CoV 555	2-15	REGN 10987	COV2-2130	S309	2-7	Brii-198	LY-CoV 1404	ADG-2	DH1047	10-40	S2X259	4-18	5-7
BA.1	<-428	-298	<-429	<-2,201	-306	<-1,496	<-2,716	<-1,716	-83.5	-6.9	-195	2.3	1.4	-11.0	-14.2	-21.1	-13.7	<-26.7	-4.1
BA.1+R346K	<-428	-135	<-429	-415	-187	<-1,496	<-2,716	<-1,716	<-687	-4.5	-82.1	<-22	1.5	-15.7	-7.9	-20.5	-7.5	<-26.7	-5.5
BA.2	<-428	-322	<-429	<-2,201	-680	<-1,496	<-2,716	-253	-1.9	-27.0	-7.3	-10.5	1.1	<-555	<-58.0	<-114	<-96	<-26.7	<-171
T19I	-3.1	-4.9	-5.3	-3.7	-1.9	-2.2	-2.0	-2.1	-1.5	-1.8	-5.1	-1.6	-1.7	-1.7	-1.5	-2.7	-2.9	-6.1	-3.3
L24S	-2.9	-4.0	-4.6	-3.2	-2.4	-2.4	-2.8	-4.2	-2.1	-1.5	-2.6	-2.2	-1.6	-1.3	-1.1	-2.4	-2.0	-3.1	-1.1
Del25-27	-1.2	-2.6	-2.0	-1.3	-1.0	-1.4	-1.2	-1.3	1.0	-1.3	-2.8	2.0	-1.2	1.1	1.6	-1.8	1.1	-23.1	-16.8
V213G	-2.5	-3.1	-3.0	-3.1	-1.5	-1.1	-1.6	-2.2	-2.0	-1.2	-3.2	-1.1	-1.5	1.1	1.0	-2.0	-1.7	1.9	-2.8
S371F	-143	-126	-95.1	-27.9	-26.1	-5.1	-6.3	-86.6	-1.3	-20.5	-30.6	<-22	-2.4	-43.0	-60.9	<-114	-77.5	7.8	2.3
T376A	-1.9	-3.1	-2.5	-2.1	-1.3	-1.7	-1.3	-1.9	-1.8	1.0	-2.7	2.0	-1.7	1.1	1.1	-1.5	-2.3	1.3	-1.3
D405N	-25.6	-2.3	-2.9	-2.8	-2.1	-1.9	-1.7	-1.6	1.0	1.5	-3.1	-1.6	1.3	3.3	-1.2	-3.9	-2.2	5.6	1.5
R408S	1.4	-1.1	-1.3	-1.1	1.5	-1.6	-1.3	1.2	1.0	1.0	1.2	1.4	-1.4	-1.6	-2.1	-1.2	-3.6	1.1	-1.3

>3
<-3
<-10
<-100

Fig. 2 | BA.2 differs in resistance profile to monoclonal antibodies.

a, Pseudovirus neutralization by monoclonal antibodies (mAbs). Values above the LOD of 10 µg ml⁻¹ (dotted line) are arbitrarily plotted to allow for

retained decent activity against BA.2 but had almost no activity against BA.1 viruses. S309 or sotrovimab lost 27-fold neutralizing activity against BA.2; this is important because it is an authorized monoclonal antibody that was found to retain activity against the original form of Omicron²⁻⁴. LY-CoV1404, the most recently authorized monoclonal antibody, remained potent in neutralizing all Omicron sublineages, suggesting that there is still a patch in this antibody-binding region that is unaffected by all spike alterations found in SARS-CoV-2 variants so far. Although there was a lack of an observable difference among the Omicron sublineages in neutralization by polyclonal sera (Fig. 1c), important antigenic differences do exist when probed by monoclonal antibodies. BA.1 seems to be more resistant to class 3 antibodies than BA.2 (except for S309), whereas BA.2 is more resistant to all class 4 antibodies tested. Our recent study² showed that previous SARS-CoV-2 variants, such as Beta (B.1.351) and Delta (B.1.617.2), evolved to resist class 1, class 2 and NTD antibodies first, and then the Omicron variant seemingly has further evolved to resist class 3 and class 4 antibodies in addition. Our current findings suggest that the Omicron sublineages may have diverged under slightly different pressure from class 3 and class 4 antibodies to the RBD.

Alterations conferring antibody resistance

Finally, we constructed each of the eight BA.2-specific spike alterations alone as pseudoviruses and tested them using the same panel of 19 monoclonal antibodies (Fig. 2b). S371F broadly affected most of the RBD-directed antibodies, similar to what was observed for S371L in BA.1 (ref. ²) but with a greater negative impact, perhaps due to the bulkier side chain of phenylalanine. Notably, S371F seems to be responsible for the loss in potency of S309, although this alteration was not observed

visualization of each sample. **b**, Fold change in IC₅₀ values relative to D614G of neutralization of Omicron variants, as well as point mutants unique to BA.2.

previously as a marker for clinical resistance to sotrovimab²⁰. CB6 was adversely affected by the D405N alteration, probably owing to its position in the epitope of this antibody¹². It is not clear how T19I and L24S alterations in the NTD subtly impaired the neutralizing activity of class 1 antibodies to the RBD.

Discussion

In summary, we have comprehensively evaluated the antigenic properties of two sublineages of the Omicron variant, BA.1+R346K and BA.2, and we believe that our results have important clinical implications. First, polyclonal sera showed a substantial loss in neutralizing activity against both sublineages, with drops comparable to that against BA.1 (Fig. 1c). These three sublineages of Omicron, therefore, seem to be antigenically equidistant from the wild-type SARS-CoV-2, probably threatening the efficacies of current coronavirus disease 2019 (COVID-19) vaccines to a similar extent. The present study, however, does not address the antigenic distance between BA.1 and BA.2, the determination of which will require cross-neutralization experiments using sublineage-specific sera. Second, monoclonal antibodies were affected in a disparate manner for the different Omicron sublineages. For clinically approved or authorized antibodies, S309 (sotrovimab) retained activity against both BA.1 and BA.1+R346K, but its activity against BA.2 has dropped 27-fold (Fig. 2b) to a 50% inhibitory concentration (IC₅₀) of about 1 µg ml⁻¹ (Fig. 2a). COV2-2130 (cilgavimab) and its combination with COV2-2196 (tixagevimab) retained activity against BA.2, but this antibody combination is authorized only for preventive use. Only the recently authorized LY-CoV1404 (bebtelovimab) could adequately treat all sublineages of the Omicron variant. As COVID-19 treatment

options are narrowed by the emergence of more and more variants, it is imperative that we continue to devise novel strategies to contain this ever-evolving pathogen.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-022-04594-4>.

1. Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature* <https://doi.org/10.1038/s41586-022-04411-y> (2022).
2. Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* **602**, 676–681 (2022).
3. Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* **602**, 664–670 (2022).
4. Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. *Nature* **602**, 657–663 (2022).
5. Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* **602**, 654–656 (2022).
6. Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. *Nature* **602**, 671–675 (2022).
7. Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290–295 (2020).
8. Shu, Y. & McCauley, J. GISAID: global initiative on sharing all influenza data - from vision to reality. *Eurosurveillance* **22**, 30494 (2017).
9. Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. *Science* **369**, 1010–1014 (2020).
10. Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. *Nature* **584**, 443–449 (2020).

11. Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. *Sci. Transl. Med.* **13**, eabf1906 (2021).
12. Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature* **584**, 120–124 (2020).
13. Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature* **584**, 115–119 (2020).
14. Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Preprint at *bioRxiv* <https://doi.org/10.1101/2021.04.30.442182> (2022).
15. Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. *Science* **371**, 823–829 (2021).
16. Li, D. et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell* **184**, 4203–4219 (2021).
17. Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. *Nature* **597**, 103–108 (2021).
18. Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* **584**, 450–456 (2020).
19. Liu, L. et al. Isolation and comparative analysis of antibodies that broadly neutralize sarbecoviruses. *Sci. Transl. Med.* (in the press).
20. Rockett, R. et al. Resistance mutations in SARS-CoV-2 Delta variant after sotrovivimab use. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2120219> (2022).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Methods

Data reporting

No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

Serum samples

For the pseudovirus neutralization experiments, identical samples from a previous study were utilized². For the authentic virus neutralization experiments, the samples are described in Extended Data Table 1. All collections were conducted under protocols reviewed and approved by the Institutional Review Board of Columbia University. All of the participants provided written informed consent.

Antibodies

Antibodies were expressed as previously described¹⁸. Briefly, VH and VL genes for each antibody were codon optimized and synthesized (GenScript), and then inserted into mammalian expression vectors. These plasmids were transiently transfected into Expi293 cells (Thermo Fisher) using polyethylenimine and cultured for 5 days, and then the antibody was purified by affinity chromatography using rProtein A Sepharose (GE). REGN10933, REGN10987, COV2-2130 and COV2-2196 were provided by Regeneron Pharmaceuticals, Bii-196 and Bii-198 were provided by Bii Biosciences, and CB6 was provided by B. Zhang and P. Kwong (NIAID).

Cells

Expi293 cells were obtained from Thermo Fisher (catalogue number A14527), Vero E6 cells were obtained from ATCC (catalogue number CRL-1586), HEK293T cells were obtained from ATCC (catalogue number CRL-3216), and Vero-E6-TMPRSS2 cells were obtained from JCRB (catalogue number JCRB1819). All cells were purchased from authenticated vendors and morphology was visually confirmed before use. All cell lines tested mycoplasma negative.

Pseudovirus production

Spike expression constructs for variant SARS-CoV-2 spikes were produced by an in-house gene synthesis method as previously described². Constructs were confirmed by sequencing, and then transfected into HEK293T cells using Lipofectamine 3000 (Thermo Fisher) according to the manufacturer's instructions. Cells were washed 24 h post-transfection with complete medium (DMEM + 10% FBS + penicillin/streptomycin) and then infected with rVSV-G-pseudotyped Δ G-luciferase (G* Δ G-luciferase, Kerafast). Cells were thoroughly washed 2 h post-infection with complete medium, and then incubated for a further 24 h at 37 °C under 5% CO₂. Pseudoviruses were then collected and incubated with anti-VSV-G hybridoma supernatant for 1 h at 37 °C (II-Hybridoma, ATCC) to neutralize residual rVSV-G. The titre of each pseudovirus was determined by serially diluting the virus in complete medium in 96-well plates, and then incubating with 40,000 Vero E6 cells for approximately 12 h at 37 °C under 5% CO₂. Following infection, luminescence was quantified using the Luciferase Assay System (Promega) according to the manufacturer's instructions and measured with a SpectraMax i3x Multi-Mode Microplate Reader (Molecular Devices) using SoftMax Pro 7.0.2 (Molecular Devices), and then the titre was determined by comparison to control wells with cells alone. Pseudoviruses were aliquoted and stored at -80 °C until use.

Pseudovirus neutralization assay

Neutralization assays were conducted in 96-well plates by serially diluting sera or antibodies in complete medium, starting at 1:100 dilution or 10 μ g ml⁻¹, respectively, and incubating with pseudoviruses for 1 h at 37 °C. Following incubation, 40,000 Vero E6 cells were added to each well, and further incubated for approximately 12 h at 37 °C under 5% CO₂. Luminescence was quantified using the Luciferase Assay System

according to the manufacturer's instructions and measured with a SpectraMax i3x Multi-Mode Microplate Reader using SoftMax Pro 7.0.2. Neutralization was determined by comparison to control wells with cells alone and with virus alone. IC₅₀ values were calculated by fitting a nonlinear five-parameter dose-response curve in GraphPad Prism version 9.2.

Authentic virus isolation and propagation

SARS-CoV-2 variants D614G (GISAID: EPI_ISL_497840) and BA.2 (GISAID: EPI_ISL_9845731) were isolated from respiratory tract specimens of patients with COVID-19 in Hong Kong by J.F.-W.C., K.-Y.Y. and colleagues at the Department of Microbiology, The University of Hong Kong. The viruses were propagated in Vero-E6-TMPRSS2 cells and the sequence was confirmed by next-generation sequencing before use.

Authentic virus neutralization assay

Vero-E6-TMPRSS2 cells were seeded in 96-well plates in complete medium overnight at 37 °C under 5% CO₂ to establish a monolayer. The following day, sera were serially diluted starting at 1:500 dilution in 96-well plates in triplicate in DMEM + 2% FBS and then incubated with 0.01 MOI of either virus at 37 °C for 1 h. Afterwards, the mixture was overlaid onto cells and further incubated at 37 °C under 5% CO₂ for approximately 72 h. Cytopathic effects were then visually assessed in all wells and scored as either negative or positive for infection by comparison to control uninfected or infected wells in a blinded manner. Neutralization curves and IC₅₀ values were derived by fitting a nonlinear five-parameter dose-response curve to the data in GraphPad Prism version 9.2.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

All experimental data are provided in the manuscript. Omicron prevalence analyses utilized sequences submitted to and available from GISAID (ref.⁸). The sequences of the authentic viruses used in this study have been deposited to GISAID (<https://www.gisaid.org/>) under the accession numbers EPI_ISL_497840 (D614G) and EPI_ISL_9845731 (BA.2). Materials use in this study will be made available under an appropriate Materials Transfer Agreement.

Acknowledgements We thank Regeneron Pharmaceuticals and B. Zhang and P. Kwong (NIAID) for antibodies. This study was supported by funding from the Gates Foundation, the JPB Foundation, A. and P. Cherng, S. Yin, C. Ludwig, D. and R. Wu, Health@InnoHK, the National Science Foundation (MCB-2032259) and the NIH SARS-CoV-2 Assessment of Viral Evolution Program.

Author contributions D.D.H. conceived this project. S.I. and Lihong Liu conducted pseudovirus neutralization experiments. Y.G. and Z.S. conducted bioinformatic analyses. Liyuan Liu and Yiming Huang constructed the spike expression plasmids. J.F.-W.C., H.C., K.K.-H.C., and T.T.-T.Y. conducted authentic virus neutralization experiments. M.W. aided sample collections. Y.L. managed the project. J.Y. expressed and purified antibodies. M.T.Y. and M.E.S. provided clinical samples. Yaoxing Huang contributed to discussions. K.-Y.Y., H.H.W., and D.D.H. directed and supervised the project. S.I., Lihong Liu and D.D.H. analysed the results and wrote the manuscript.

Competing interests S.I., Lihong Liu, J.Y., Yaoxing Huang and D.D.H. are inventors on patent applications (WO2021236998) or provisional patent applications (63/271,627) filed by Columbia University for a number of SARS-CoV-2 neutralizing antibodies described in this manuscript. Both sets of applications are under review. D.D.H. is a co-founder of TailMed Biologics and RenBio, consultant to WuXi Biologics and Bii Biosciences, and board director for Vicarious Surgical.


Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41586-022-04594-4>.

Correspondence and requests for materials should be addressed to David D. Ho.

Peer review information Nature thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1 | Serum neutralization of authentic viruses. Authentic virus neutralization by vaccinee sera. $n = 10$ and 13 biologically independent serum samples, respectively, for two doses mRNA and three doses mRNA groups. Values above points indicate the geometric mean. Numbers in

parentheses denote the number of samples above the limit of detection (LOD) of 500. Values below the LOD and those that overlap are plotted to allow for visualization of each sample. P values were determined by two-sided Wilcoxon matched-pairs signed rank test.

Extended Data Table 1 | Demographics and vaccination information for serum samples from vaccinated individuals used in authentic virus neutralization experiments

Vaccine Sample	Vaccine type	Days post-vaccination (after last dose)	Documented COVID Infection	Age	Gender
Two doses #1	mRNA-1273 + mRNA-1273	32	No	68	Male
Two doses #2	BNT162b2 + BNT162b2	22	No	57	Female
Two doses #3	BNT162b2 + BNT162b2	16	No	64	Female
Two doses #4	BNT162b2 + BNT162b2	21	No	45	Male
Two doses #5	mRNA-1273 + mRNA-1273	32	No	66	Female
Two doses #6	BNT162b2 + BNT162b2	213	Yes	66	Male
Two doses #7	BNT162b2 + BNT162b2	14	No	52	Female
Two doses #8	BNT162b2 + BNT162b2	8	No	67	Male
Two doses #9	BNT162b2 + BNT162b2	50	No	61	Female
Two doses #10	BNT162b2 + BNT162b2	102	No	39	Male
Three doses #1	mRNA-1273 + mRNA-1273 + mRNA-1273	29	No	66	Female
Three doses #2	BNT162b2 + BNT162b2 + BNT162b2	14	No	64	Female
Three doses #3	BNT162b2 + BNT162b2 + BNT162b2	34	No	45	Male
Three doses #4	BNT162b2 + BNT162b2 + BNT162b2	15	No	50	Female
Three doses #5	BNT162b2 + BNT162b2 + BNT162b2	15	No	48	Female
Three doses #6	BNT162b2 + BNT162b2 + BNT162b2	90	No	59	Male
Three doses #7	BNT162b2 + BNT162b2 + BNT162b2	87	No	66	Female
Three doses #8	mRNA-1273 + mRNA-1273 + mRNA-1273	23	Yes	28	Female
Three doses #9	BNT162b2 + BNT162b2 + BNT162b2	14	No	75	Female
Three doses #10	BNT162b2 + BNT162b2 + BNT162b2	14	No	78	Male
Three doses #11	mRNA-1273 + mRNA-1273 + BNT162b2	60	Yes	64	Male
Three doses #12	BNT162b2 + BNT162b2 + mRNA-1273	15	Yes	39	Male
Three doses #13	BNT162b2 + BNT162b2 + BNT162b2	53	No	30	Male

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All experimental data are provided in the manuscript. Omicron prevalence analyses utilized sequences submitted to and available from GISAID. The sequences of the authentic viruses used in this study are available at GISAID under accession numbers EPI_ISL_497840 (D614G) and EPI_ISL_9845731 (BA.2).

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We used analogous sample sizes as in previous work (e.g. Wang et al 2021, Nature, Liu et al 2021, Nature), which we had previously determined to be sufficient sample sizes for comparisons between groups for these experiments.
Data exclusions	No data were excluded.
Replication	The key results, the serum neutralization of D614G and BA.2 (both in pseudoviruses and authentic viruses), and the neutralization of all of the viruses in Fig. 2b by S309, were repeated twice independently in technical triplicate with similar results. The results that are shown are representative. Other experiments were conducted in technical triplicate and not repeated, as these results were consistent with bioinformatic and structural analyses.
Randomization	As this is an observational study, randomization is not relevant.
Blinding	As this is an observational study, investigators were not blinded.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

Methods

n/a	Involved in the study	n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies	<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms		
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data		
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern		

Antibodies

Antibodies used	All of the antibodies used in this study were produced in our laboratory or received from other laboratories. 1-20, LY-CoV555, 2-15, S309, 2-7, LY-CoV1404, ADG-2, DH1047, 10-40, S2X259, 4-18, and 5-7 were expressed and purified in-house as described previously in Liu et al 2020, Nature and in the Methods section of this manuscript. REGN10987, REGN10933, COV2-2196, and COV2-2130 were produced and provided by Regeneron Pharmaceuticals, Brie-196 and Brie-198 were produced and provided by Brie Biosciences, CB6 was produced and provided by Baoshan Zhang and Peter Kwong (NIAID).
Validation	All of the antibodies except LY-CoV1404 have been validated in previous studies both by binding to SARS-CoV-2 spike and neutralization of SARS-CoV-2 (both pseudovirus and authentic virus), and when applicable, have been confirmed to give similar results as that described in publications by other groups. Specifically, 1-20 and 4-18 were tested in Liu et al 2020, Nature, CB6, Brie-196, 910-30, REGN10933, COV2-2196, LY-CoV555, 2-15, REGN10987, COV2-2130, S309, 2-7, Brie-198, and 5-7 were tested in Wang et al 2021, Nature, and ADG-2, DH1047, 10-40, and S2X259 were tested in Liu et al 2021, bioRxiv. LY-CoV1404 was newly produced and tested prior to use in this study and confirmed to have similar results as that of the original publication from which it is derived (Westendorf et al 2022, bioRxiv).

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	Expi293 cells were obtained from Thermo Fisher (Catalog #A14527), Vero E6 cells were obtained from ATCC (Catalog
---------------------	--

Cell line source(s)	#CRL-1586), HEK293T cells were obtained from ATCC (Catalog #CRL-3216), and Vero-E6-TMPRSS2 cells were obtained from JCRB (Catalog #JCRB1819).
Authentication	Cell lines were purchased from authenticated vendors, and morphology was also confirmed visually prior to use.
Mycoplasma contamination	Cell lines tested mycoplasma negative.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified cell lines were used in this study.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	<p>Population characteristics for the sera utilized in the pseudovirus neutralization assays are described in Extended Data Table 1 of Liu et al 2021, Nature (ref 2). Convalescent samples had the following ranges: 9-120 days post-symptoms, 45-79 years old, 4/10 female, 6/10 male. We presume all of these individuals were infected with the wild-type strain of SARS-CoV-2 as these samples were collected in Spring of 2020. Vaccinee samples had the following ranges: 6-213 days post-vaccination, 26-78 years old, 12/40 two mRNA-1273 vaccinations, 13/40 two BNT162b2 vaccinations, 2/40 three mRNA-1273 vaccinations, 13/40 three BNT162b2 vaccinations, 1/40 previously infected, 39/40 uninfected, 20/40 female, 20/40 male.</p> <p>Population characteristics for the vaccinee sera utilized in the authentic virus neutralization assays are described in Extended Data Table 1 of this manuscript. These samples had the following ranges: 8-213 days post-vaccination, 28-78 years old, 2/23 two mRNA-1273 vaccinations, 8/23 two BNT162b2 vaccinations, 2/23 three mRNA-1273 vaccinations, 9/23 three BNT162b2 vaccinations, 1/23 two mRNA-1273 vaccinations followed by one BNT162b2 vaccination, 1/23 two BNT162b2 vaccination followed by one mRNA-1273 vaccination, 4/23 previously infected, 19/23 uninfected, 12/23 female, 11/23 male.</p>
Recruitment	For convalescent sera, convalescing patients volunteered and were enrolled in an observational cohort study at Columbia University Irving Medical Center in Spring of 2020. For the vaccinee sera, individuals volunteered and were enrolled in an observational cohort study at Columbia University Irving Medical Center to study the immunological responses to SARS-CoV-2 in individuals who had received COVID-19 vaccines. Self-selection biases may have affected the demographics of the enrolled population, but are not expected to have impacted the results of this study. High titer samples were specifically chosen within each of the serum groups so that fold-change in titer could be better determined.
Ethics oversight	All collections were conducted under protocols reviewed and approved by the Institutional Review Board of Columbia University. All of the participants provided written informed consent.

Note that full information on the approval of the study protocol must also be provided in the manuscript.